Mirae Asset Global Investments Co. Ltd. Purchases 1,199 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,921 shares of the company’s stock after acquiring an additional 1,199 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Dyne Therapeutics were worth $305,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Vivo Capital LLC boosted its position in shares of Dyne Therapeutics by 79.2% during the 3rd quarter. Vivo Capital LLC now owns 1,035,136 shares of the company’s stock worth $9,275,000 after purchasing an additional 457,494 shares in the last quarter. Braidwell LP lifted its position in Dyne Therapeutics by 32.2% in the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock valued at $16,325,000 after acquiring an additional 444,100 shares in the last quarter. Armistice Capital LLC lifted its position in Dyne Therapeutics by 31.6% in the 3rd quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock valued at $10,752,000 after acquiring an additional 288,000 shares in the last quarter. Walleye Capital LLC bought a new position in Dyne Therapeutics in the 3rd quarter valued at about $2,511,000. Finally, Assenagon Asset Management S.A. lifted its position in Dyne Therapeutics by 24.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 721,474 shares of the company’s stock valued at $6,464,000 after acquiring an additional 142,083 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 4.4 %

Shares of DYN stock opened at $24.73 on Friday. The company has a 50 day moving average of $26.10 and a 200-day moving average of $17.87. Dyne Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $30.27. The firm has a market cap of $2.13 billion, a P/E ratio of -6.28 and a beta of 0.95.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17). As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.25 EPS for the current year.

Insider Activity at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 3,429 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $94,297.50. Following the completion of the transaction, the senior vice president now directly owns 124,228 shares in the company, valued at approximately $3,416,270. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, major shareholder Venture Fund Xi L.P. Atlas sold 162,707 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $23.14, for a total value of $3,765,039.98. Following the completion of the transaction, the insider now directly owns 6,985,504 shares in the company, valued at approximately $161,644,562.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 3,429 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total transaction of $94,297.50. Following the completion of the transaction, the senior vice president now directly owns 124,228 shares of the company’s stock, valued at $3,416,270. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,875,432 shares of company stock worth $44,368,530. Corporate insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Raymond James raised their price target on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a research report on Thursday, January 4th. Piper Sandler raised their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Chardan Capital increased their price objective on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 8th. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $37.43.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.